Tumor angiogenesis—characteristics of tumor endothelial cells

International Journal of Clinical Oncology

Volumn 21, Issue 2, 2016, Pages 206-212

  Hida, Kyoko ^a   Maishi, Nako ^a   Torii, Chisaho ^a   Hida, Yasuhiro ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti angiogenic therapy; Blood vessel; Metastasis; Tumor angiogenesis; Tumor endothelial cell

Indexed keywords

ANGIOGENESIS INHIBITOR; DOXORUBICIN; FLUOROURACIL; MEMBRANE PROTEIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR PAX2; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN D; VINCRISTINE;

ANGIOGENESIS; CANCER RESISTANCE; CANCER THERAPY; ENDOTHELIUM CELL; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR ENDOTHELIAL CELL; TUMOR MICROENVIRONMENT; VASCULAR TUMOR; ANIMAL; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84958039295     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-016-0957-1     Document Type: Review

References (56)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186
2. Folkman J, Kerbel R (2002) Role of angiogenesis in tumor growth and metastasis. Clinical translation of angiogenesis inhibitors. Semin Oncol 29(6 Suppl 16):15–18
3. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6(4):273–286
4. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184–2191
5. Keedy VL, Sandler AB (2007) Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci 98(12):1825–1830
6. Kindler HL, Friberg G, Singh DA et al (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23(31):8033–8040
7. Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14(6):1860–1869
8. Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6):553–563
9. Zhang L, Takara K, Yamakawa D, et al (2015) Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy. Cancer Sci 107(1):36–44
10. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410
11. Goh PP, Sze DM, Roufogalis BD (2007) Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets 7(8):743–758
12. McDonald DM, Choyke PL (2003) Imaging of angiogenesis: from microscope to clinic. Nat Med 9(6):713–725
13. Hashizume H, Baluk P, Morikawa S et al (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156(4):1363–1380
14. Kalluri R (2003) Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3(6):422–433
15. Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15(1):102–111
16. McDonald DM, Baluk P (2002) Significance of blood vessel leakiness in cancer. Cancer Res 62(18):5381–5385
17. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58–62
18. Chang YS, di Tomaso E, McDonald DM et al (2000) Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97(26):14608–14613
19. Langenkamp E, Molema G (2009) Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res 335(1):205–222
20. Arap W, Kolonin MG, Trepel M et al (2002) Steps toward mapping the human vasculature by phage display. Nat Med 8(2):121–127
21. Trepel M, Arap W, Pasqualini R (2002) In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 6(3):399–404
22. Hida K, Hida Y, Amin DN et al (2004) Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64(22):8249–8255
23. Arbiser JL, Raab G, Rohan RM et al (1999) Isolation of mouse stromal cells associated with a human tumor using differential diphtheria toxin sensitivity. Am J Pathol 155(3):723–729
24. Croix BS, Rago C, Velculescu V et al (2000) Genes expressed in human tumor endothelium. Science 289(5482):1197–1202
25. Seaman S, Stevens J, Yang MY et al (2007) Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11(6):539–554
26. Carson-Walter EB, Watkins DN, Nanda A et al (2001) Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61(18):6649–6655
27. Nanda A, Croix BS (2004) Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol 16(1):44–49
28. Buckanovich RJ, Sasaroli D, O’Brien-Jenkins A et al (2007) Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 25(7):852–861
29. Lu C, Bonome T, Li Y et al (2007) Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67(4):1757–1768
30. Hida K, Klagsbrun M (2005) A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 65(7):2507–2510
31. Amin DN, Hida K, Bielenberg DR et al (2006) Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 66(4):2173–2180
32. Tsuchiya K, Hida K, Hida Y et al (2010) Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization. Int J Oncol 36(6):1379–1386
33. Matsuda K, Ohga N, Hida Y et al (2010) Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem Biophys Res Commun 394(4):947–954
34. Kurosu T, Ohga N, Hida Y et al (2011) HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br J Cancer 104(5):819–829
35. Bussolati B, Deambrosis I, Russo S et al (2003) Altered angiogenesis and survival in human tumor-derived endothelial cells. Faseb J 17(9):1159–1161
36. Matsuda K, Ohga N, Hida Y, et al (2010) Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem Biophys Res Commun 394(4):947–954
37. Bussolati B, Grange C, Bruno S et al (2006) Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures. Exp Cell Res 312(6):913–924
38. Fonsato V, Buttiglieri S, Deregibus MC et al (2006) Expression of Pax2 in human renal tumor-derived endothelial cells sustains apoptosis resistance and angiogenesis. Am J Pathol 168(2):706–713
39. Akino T, Hida K, Hida Y et al (2009) Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 175(6):2657–2667
40. Ricci-Vitiani L, Pallini R, Biffoni M et al (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468(7325):824–828
41. Wang R, Chadalavada K, Wilshire J et al (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468(7325):829–833
42. Xiong YQ, Sun HC, Zhang W et al (2009) Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 15(15):4838–4846
43. Akiyama K, Ohga N, Hida Y et al (2012) Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. Am J Pathol 180(3):1283–1293
44. Mundhekar AN, Bullard DC, Kucik DF (2006) Intracellular heterogeneity in adhesiveness of endothelium affects early steps in leukocyte adhesion. Am J Physiol Cell Physiol 291(1):C130–C137
45. Molema G (2010) Heterogeneity in endothelial responsiveness to cytokines, molecular causes, and pharmacological consequences. Semin Thromb Hemost 36(3):246–264
46. Saubamea B, Cochois-Guegan V, Cisternino S et al (2012) Heterogeneity in the rat brain vasculature revealed by quantitative confocal analysis of endothelial barrier antigen and P-glycoprotein expression. J Cereb Blood Flow Metab 32(1):81–92
47. Dudley AC, Khan ZA, Shih SC et al (2008) Calcification of multipotent prostate tumor endothelium. Cancer Cell 14(3):201–211
48. Ohga N, Ishikawa S, Maishi N et al (2012) Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors. Am J Pathol 180(3):1294–1307
49. Bussolati B, Assenzio B, Deregibus MC et al (2006) The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. J Mol Med (Berl) 84(10):852–863
50. Adya R, Tan BK, Punn A et al (2008) Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3 K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 78(2):356–365
51. Naito H, Kidoya H, Sakimoto S et al (2011) Identification and characterization of a resident vascular stem/progenitor cell population in preexisting blood vessels. EMBO J 31(4):842–855
52. Ohmura-Kakutani H, Akiyama K, Maishi N et al (2014) Identification of tumor endothelial cells with high aldehyde dehydrogenase activity and a highly angiogenic phenotype. PLoS One 9(12):e113910
53. Sato Y (2011) Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy. Cancer Sci 102(7):1253–1256
54. Helfrich I, Scheffrahn I, Bartling S et al (2010) Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 207(3):491–503
55. Taylor SM, Nevis KR, Park HL et al (2010) Angiogenic factor signaling regulates centrosome duplication in endothelial cells of developing blood vessels. Blood 116(16):3108–3117
56. Gao D, Nolan D, McDonnell K, et al (2009) Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 1796(1):33–40